drugset / Trial / NCT03341715

Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN

NCT03341715

Phase 0 Completed 18 enrolled Yale University
RandomizedCrossoverDouble-blindPrevention

Summary

The purpose of this pilot study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a 1-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

Timeline

Start
2018-06-01
Primary completion
2019-11-13
Completion
2019-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavoglurant Small molecule 200 mg

Indications

No indication recorded.